Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,099 public trials 2,041 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

NCT03288480

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Cancer Center Phoenix, Arizona, United States
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
  • Mayo Clinic Cancer Center Jacksonville, Florida, United States
  • Mayo Clinic Cancer Center Rochester, Minnesota, United States
View Trial Details
Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

NCT02514668

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Investigational Site Number 840003 Scottsdale, Arizona, United States
  • Investigational Site Number 840004 San Francisco, California, United States
  • Investigational Site Number 840011 Detroit, Michigan, United States
  • Investigational Site Number 840015 St Louis, Missouri, United States
View all 18 locations
View Trial Details
Completed

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

NCT02448381

Conditions
Cutaneous T-Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • University of Arizona Phoenix, Arizona, United States
  • Mayo Clinic Scottsdale, Arizona, United States
  • University of Arkansas Little Rock, Arkansas, United States
View all 33 locations
View Trial Details
Completed

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

NCT02631577

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University Miami Miami, Florida, United States
  • Norton Medical Plaza II Louisville, Kentucky, United States
  • Memorial Sloan-Kettering Cancer Center; Hematology/Oncology New York, United States
View all 16 locations
View Trial Details

Related conditions